84404-04-6

Basic information

• Product Name: METHYL 4-[(3,4-DICHLOROBENZYL)OXY]BENZENECARBOXYLATE
• Synonyms: METHYL 4-[(3,4-DICHLOROBENZYL)OXY]BENZENECARBOXYLATE;RARECHEM AL BF 1027;4-(3,4-dichlorobenzyl)oxybenzoic acid methyl ester;4-[(3,4-dichlorophenyl)methoxy]benzoic acid methyl ester;9N-063;Bionet2_000637;methyl 4-[(3,4-dichlorobenzyl)oxy]benzoate;methyl 4-[(3,4-dichlorophenyl)methoxy]benzoate
• CAS NO: 84404-04-6
• Molecular Formula: C₁₅H₁₂Cl₂O₃
• Molecular Weight: 311.16
• Mol File: 84404-04-6.mol
• Article Data: 5

Chemical Properties

• Melting Point: 120-122°C
• Appearance: /
• CAS DataBase Reference: METHYL 4-[(3,4-DICHLOROBENZYL)OXY]BENZENECARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-[(3,4-DICHLOROBENZYL)OXY]BENZENECARBOXYLATE(84404-04-6)
• EPA Substance Registry System: METHYL 4-[(3,4-DICHLOROBENZYL)OXY]BENZENECARBOXYLATE(84404-04-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 84404-04-6(Hazardous Substances Data)

Upstream product

• 102-47-6 3,4-Dichlorophenylmethyl chloride 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 18880-04-1 3,4-dichlorobenzyl bromide 

Downstream Products

• 1322084-32-1 {1-[4-(3,4-dichloro-benzyloxy)-benzyl]-3,5-dimethyl-1H-pyrazol-4-yl}-acetic acid 
• 175136-14-8 (4-[(3,4-dichlorobenzyl)oxy]phenyl)methanol 
• 56442-18-3 4-(3,4-dichlorobenzyloxy)benzoic acid 
• 1355631-29-6 4-[(3,4-dichlorobenzyl)oxy]-N-(methylsulfonyl)benzamide 

Relevant articles and documents

Design and biological evaluation of phenyl imidazole analogs as hedgehog signaling pathway inhibitors

The hedgehog (Hh) signaling pathway is involved in diverse aspects of cellular events. Aberrant activation of Hh signaling pathway drives oncogenic transformation for a wide range of cancers, and it is therefore a promising target in cancer therapy. In the principle of association and ring-opening, we designed and synthesized a series of Hh signaling pathway inhibitors with phenyl imidazole scaffold, which were biologically evaluated in Gli-Luc reporter assay. Compound 25 was identified to possess high potency with nanomolar IC50, and moreover, it preserved the inhibition against wild-type and drug-resistant Smo-overexpressing cells. A molecular modeling study of compound 25 expounded its binding mode to Smo receptor, providing a basis for the further structural modification of phenyl imidazole analogs.

CHEMICAL COMPOUNDS

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein X, Ar1, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS

The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2-activity, wherein W, L1, L2, X, L3, Y, R1 and R2 are as defined in the spe